Abstract
In this issue of Blood, Santagostino et al, in their phase 3 study, demonstrate efficacy and safety of recombinant fusion protein linking coagulation factor IX (FIX) with albumin (rIX-FP) which, along with the other 2 extended half-life FIX products, heralds a new era for the treatment of hemophilia B.
Cite
CITATION STYLE
APA
Taylor, J. A., & Kruse-Jarres, R. (2016). A new era for hemophilia B treatment. Blood, 127(14), 1734–1736. https://doi.org/10.1182/blood-2016-02-694869
Register to see more suggestions
Mendeley helps you to discover research relevant for your work.
Already have an account? Sign in
Sign up for free